EVMN4:05 PMEvommune Reports First Quarter 2026 Financial Results and Provides Business Highlightsevommune.com
EVMN9:00 AMEvommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraineevommune.com
EVMN4:01 PMEvommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlightsevommune.com